Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, has announced a $12 million financing extension, bringing the Company's total Series C funding to $87 million. Elevage Medical Technologies and Jonathan Milner led the raise, joined by existing investors British Business Bank and GK Goh. The investment will accelerate the integration of antibody expression and binding validation capabilities into the Company's eProtein Discovery benchtop system, which enables multiplex protein screening, characterization, and expression in-house.

Nuclera exists to remove uncertainty from protein science. As the pioneer of multiplex protein screening, the company helps researchers start with clarity, so ideas move faster to result. Nuclera believes access to your protein should be a certainty, not a gamble. eProtein Discovery™ is how they deliver on that promise, but our aim is bigger: to make protein access routine for every lab, accelerate breakthroughs in human health, and empower scientists to spend more time on discovery and less on delay.